Methods for predicting and improving therapeutic efficacy of cancer treatments and methods for cancer prognosis
OwnerFrancesco DE SANCTIS, Vincenzo BRONTE +1inventors
InventorsFrancesco DE SANCTIS, Vincenzo BRONTE, Michael ERDELJAN
Life of this patent
Estimating the term…
Abstract
The present invention provides a prognostic marker in human cancer, CLDN18. Methods involving this marker are disclosed for predicting therapeutic efficacy of cancer treatments and the prognosis of cancer. The present invention also provides a method for selecting a subject affected with a cancer for an immunotherapy. Furthermore, the present invention provides a therapy for treating cancer.
Claims68
A method for determining the ability of a cancer patient to mount a natural or immunotherapy-induced immune response against the cancer comprising determining the expression level of claudin 18 (CLDN18) in a sample obtained from the patient.
A method for determining the survival perspective of a cancer patient comprising determining the expression level of claudin 18 (CLDN18) in a sample obtained from the patient.
A method for determining the responsiveness of a cancer patient to immunotherapy comprising determining the expression level of claudin 18 (CLDN18) in a sample obtained from the patient.
A method for treating a cancer patient, the method comprising:
- (i) determining the expression level of claudin 18 (CLDN18) in a sample obtained from the patient and
- (ii) administering an immunotherapy to the patient, if the patient is found to be eligible in (i).
A method for treating a cancer patient, the method comprising:
- (i) determining that a sample obtained from the patient has an expression level of claudin 18 (CLDN18) at or above a reference level and
- (ii) administering an immunotherapy to the patient.
A method for enhancing the ability of a cancer patient to mount a natural or immunotherapy-induced immune response against the cancer comprising administering an agent stabilizing or increasing expression of claudin 18 (CLDN18).
A method for enhancing the responsiveness of a cancer patient to immunotherapy comprising administering an agent stabilizing or increasing expression of claudin 18 (CLDN18).
A method for treating a cancer patient, the method comprising:
- (i) administering an agent stabilizing or increasing expression of claudin 18 (CLDN18) and
- (ii) administering an immunotherapy to the patient.
A method for treating a cancer patient, the method comprising:
- (i) determining the expression level of claudin 18 (CLDN18) in a tumor biopsy sample obtained from the patient
- (ii) comparing the expression level of CLDN18 to a reference, and
- (iii) administering an immunotherapy to the patient when the expression level of CLDN18 is higher than the reference.
A method for treating a cancer patient, the method comprising administering immunotherapy to a patient having been determined to have a tumor that expresses claudin 18 (CLDN18).
A method for treating a cancer patient, the method comprising administering immunotherapy to a patient having been determined to have a tumor that expresses claudin 18 (CLDN18) at a level higher than a reference.
A method of increasing therapeutic T-cell migration to a tumor in the patient, the method comprising administering to the patient an agent that stabilizes or increases expression of claudin 18 (CLDN18).
A method for treating a tumor in a patient, the method comprising administering to the patient immunotherapy in combination with an agent that stabilizes or increases expression of claudin 18 (CLDN18) if the patient has been determined to have a tumor that does not express CLDN18 or that expresses CLDN18 at a level lower than a reference.
Dependencies are inferred from the claim text.